Form III-like conformation and Form I-like packing in a chloroform channel solvate of the diuretic drug chlortalidone by Martins, Felipe T. et al.
  Universidade de São Paulo
 
2012
 
Form III-like conformation and Form I-like
packing in a chloroform channel solvate of the
diuretic drug chlortalidone
 
 
CRYSTENGCOMM, CAMBRIDGE, v. 14, n. 19, pp. 6173-6177, APR, 2012
http://www.producao.usp.br/handle/BDPI/33717
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Física e Ciência Interdisciplinar - IFSC/FCI Artigos e Materiais de Revistas Científicas - IFSC/FCI
Form III-like conformation and Form I-like packing in a chloroform
channel solvate of the diuretic drug chlortalidone{
Felipe T. Martins,a Polyana J. de abreu,b Lilian C. Azarias,b Paulo C. M. Villis,b Ariane C. de Campos
Melo,a Javier Ellenac and Antoˆnio C. Doriguetto*b
Received 16th May 2012, Accepted 22nd June 2012
DOI: 10.1039/c2ce25766a
Chlortalidone (CTD) is an antihypertensive drug for which
only two solid state phases have been structurally elucidated
thus far. Here, we have prepared a chloroform solvate thereof,
namely, CTD Form IV, and its structure was compared to
those of Form I and Form III. Its two conformers exhibit a
dual structural feature in relation to the antecedent poly-
morphs. Both CTD molecules of Form IV adopt a Form III-
like conformation, which is featured, if the conformation of
CTD Form I is used as a reference, by a rotation of about 90u
on the axis of the C–C bond bridging the substituted benzene
and isoindolinyl rings. However, CTD Form IV assembles as in
the Form I crystal packing despite the different stacking fashion
of their centrosymmetric dimers. In contrast to Form I, there is
no offset stacking in Form IV, which forces a bend of ca. 24u
between the planes passing through the isoindolinyl moieties of
two [100]-stacked dimers. Chloroform molecules at a maximum
stoichiometry of 0.25 mol per mol of the drug play a stabilizing
role in the assembly of Form IV by filling the channels formed
on the crystals.
Chlortalidone (2-chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benze-
nesulfonamide, CTD) is an antihypertensive drug whose clinical
use has been widespread for over 50 years.1 Oral solid dosage
forms of CTD are marked by Novartis under the brand name
Higroton. Resembling another structurally related active pharma-
ceutical ingredient belonging to the thiazide class, namely,
hydrochlorothiazide (HCTZ), CTD is a thiazide-like diuretic agent
acting as sodium–chloride cotransporter inhibitor across the renal
tubular epithelium.2,3 CTD also inhibits carbonic anhydrase due to
an effective zinc binding function of its sulfonamide moiety,
accounting for part of its diuretic action.4 Undesirable effects such
as hypokalemia is associated with CTD therapy as a result of
potassium excretion increasing mediated by the sodium–potassium
exchange through the renal tubules.5 Furthermore, the risk of
developing hypokalemia is CTD dose-dependent.6 For that
reason, CTD bioavailability plays a decisive role in avoiding
undesirable effects such as hypokalemia. In this way, the CTD
amount to be delivered from solid formulations should be
rigorously controlled in order to keep the steady-state serum levels
of the drug in the appropriate dose range.
Crystal polymorphism can directly affect drug delivery from
formulated products due to possible changes in solubility and
dissolution profiles of solid state forms.7,8 Therefore, drug
bioavailability can depend on solid state polymorphism. In the
case of CTD, polymorphism should be accounted for because of
the dose-related hypokalemia risk.6 Three CTD polymorphs are
known, namely, Form I,9,10 Form II11 and Form III,10 the first one
being incorporated into medicine formulations. However, no
knowledge on phase transformations among CTD solid state
exists, even though conversion of one polymorph into another one
can result in bioavailability changes.
In fact, the solid state behavior of CTD has not been well
investigated. Only since the end of the past decade has the
polymorphism characterization of CTD advanced. In 2009, the
third CTD polymorph (Form III) was discovered by our research
group and its crystal structure was determined.10 In the same
study, the Form I crystal structure was elucidated for the first time,
increasing our understanding of the CTD assembly in the solid
state. Even so, the structure of Form II yet remains unknown.
We maintain interest in filling this 50-year gap between the
beginning of antihypertensive therapy with CTD and the
comprehension of its structural and physicochemical properties
in the solid state. Such knowledge can not be neglected because of
the risks to health resulting from undesirable bioavailability
undergone by a non-therapeutic CTD polymorph. As part of our
ongoing investigations of CTD polymorphism, crystallization
screenings were performed in attempt to obtain Form II as single
crystals suitable for X-ray diffraction structure determination
experiment. Surprisingly, another CTD crystal phase was
discovered in this course. In the present study, we report the
preparation and the X-ray diffraction crystal structure of a new
solid state form, namely, CTD Form IV, a chloroform solvate of
the drug.{ By comparing its supramolecular and conformational
features to those of the other two polymorphs whose solid state
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structures were determined previously, it was possible to observe
that Form IV is similar to Form I in terms of crystal packing and
similar to Form III in terms of molecular conformation. The
chloroform role in the assembly of Form IV is also proposed in
this study. The findings reported in this paper reinforce the need
for further studies dealing with the CTD solid state characteriza-
tion, such as the elucidation of the CTD Form II crystal structure,
the determination of thermodynamic relationships among the
CTD forms, and the establishment of links between solid state
structures and properties.
The structure of CTD Form IV was solved in centrosymmetric
triclinic space group P1¯ with one pair of enantiomeric drug
molecules in the asymmetric unit and a chloroform fraction of ca.
0.50 (Fig. 1).§ As a consequence of the space group symmetry
crystallizing CTD Form IV, two enantiomeric pairs are present in
its unit cell, wherein each enantiomer adopts two similar (but not
identical) conformations. Therefore, the drug molecules in the
asymmetric unit of CTD Form IV were labeled as conformers A
and B. CTD Form I and Form III also crystallized in the
centrosymmetric triclinic space group P1¯, but with one drug
molecule in the asymmetric unit instead. Consequently, the cell
volume of CTD form IV is more than twice those of the
antecedent polymorphs. It is important to observe that chloroform
molecules are hosted into channels assembled within the crystals,
being involved only in very weak non-classical C–H…O and
C–H…Cl hydrogen bonding and van der Waals interactions with
drug molecules (see below). Although a chloroform site occupancy
factor (SOF) of ca. 0.50 was found from the refinement,
corresponding to 0.25 mol of chloroform per mol of CTD, this
solid state phase is better described perhaps as a nonstoichiometric
chloroform solvate rather than 0.25-chloroform solvate because of
its channel solvate nature and the weakness of the interactions
keeping the solvent molecules anchored within the holes. Since the
maximum chloroform SOF is 0.50, this crystal form would be
expected to have 0.25 chloroform per CTD molecule as the highest
solvent content possible, but a lower CHCl3 amount can occur
into the channels due to solvent loss.
As shown in Tables S1 and S2 in the ESI,{ one can see that the
intramolecular geometry of both conformers A and B in CTD
Form IV does not change considerably in terms of bond lengths
and valence angles. By inspecting these tables, it is possible to
observe that these conformers also exhibit bond lengths and angles
similar to those of CTD Form I and Form III. Indeed, CTD Form
I and Form III are classical cases of conformational polymorphs,
which mainly differ by the substituted benzene ring orientation.
The four CTD conformers in the three crystal forms show
different orientations for the chlorobenzenesulfonamide head
as a result of a C1–C9 bond axis rotation. In Form IV, both
conformers in the asymmetric unit exhibit similar orientations of
the substituted benzene ring which are more resembled that of
Form III than that of Form I. The phenyl plane lies almost above
the N1–C1 bond in both conformers of CTD Form IV and in
Form III, while in the CTD Form I structure, the substituted
benzene is positioned above the C1–C8 bond. In Fig. 2,
R-enantiomers in the two conformations of CTD Form IV are
superimposed themselves and on the R-enantiomers of Form I and
Form III. The X–C1–C9–Y dihedral angles of both conformers
assembling CTD form IV are shown in Table 1 comparatively to
the corresponding measurements of CTD Form I and Form III.
The values of these torsions change by approximately 90u between
the conformers of Form IV and that of Form I, which is in
agreement with the above-mentioned rotation order on the C1–C9
bond axis. These differences did not reach 90u due to the
occurrence of small bends within the isoindolinyl ring of Form I,
since all atoms of the isoindolinyl rings are almost completely
coplanar in both conformers of CTD Form IV. If a least-squares
Fig. 1 (a) Asymmetric unit and (b) unit cell content of CTD Form IV. In the panel (a), hydrogen and non-hydrogen atoms are drawn as arbitrary radius
spheres and 30% probability thermal ellipsoids, respectively. In both panels, the atoms of each chloroform molecule depicted have site occupancy factors of
0.50.
Fig. 2 Superposition of the CTD conformers (R-enantiomers) in Form
I,10 Form III10 and Form IV. The hydrogen atoms were hidden for the
representation clarity.
6174 | CrystEngComm, 2012, 14, 6173–6177 This journal is  The Royal Society of Chemistry 2012
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plane is fitted through the isoindolinyl ring, O1 oxygen atom of
CTD Form I deviates from it by 0.107(2) A˚ (with a root mean
square deviation (r.m.s.d.) for the eight N1, C2, C3, C4, C5, C6,
C7 and C8 fitted atoms of 0.0233 A˚), while the distance of the
corresponding oxygen atom from the same least-squares plane
calculated for CTD Form IV is either 0.016(3) A˚ for conformer A
(with r.m.s.d. for the eight fitted atoms of 0.0053 A˚) or 0.019(3) A˚
for conformer B (with r.m.s.d. for the eight fitted atoms of
0.0054 A˚). Consequently, the dihedral angles formed by the O1
oxygen are altered. Likewise, the C1 carbon atom of CTD Form
III is more deviated from the isoindolinyl plane than its O1
oxygen, which rationalizes the differences in the values of the
X–C1–C9–Y dihedral angles between this polymorph and the
conformers of Form IV (Table 1). The C1 atom of CTD Form III
deviates from the least-squares isoindolinyl plane by 0.092(2) A˚
(with r.m.s.d. for the eight fitted atoms of 0.0070 A˚), while this
carbon is separated from the same least-squares plane calculated
for CTD Form IV by either 0.013(5) A˚ for conformer A or
0.023(5) A˚ for conformer B.
As can be observed in Table 1, the conformation of the
sulfonamide moiety in both conformers of CTD Form IV is
slightly different from those of Form I and Form III. A slight left
rotation on the C11–S1 bond axis is responsible for deviations of
the X–C11–S1–Y dihedral angles in both conformers of Form IV
from those in the antecedent polymorphs (Table 1). This rotation
is related to the hydrogen bonding patterns of the sulfonamide
moiety in the three solid state forms. In Form I and Form III there
are intermolecular hydrogen bonds in which the O4 oxygen atom
is acceptor from the amine N2–H2c hydrogen bonding donor
group. In these polymorphs, two N2–H2c…O4 interactions give
rise to centrosymmetric dimers hydrogen bonded through their
sulfonamide moieties forming a R22(10) assembly.
12 On the other
hand, in Form IV the N2–H2c donor group interacts with the
other SO2 oxygen, namely, O3. Geometric parameters of classical
hydrogen bonds present in CTD Form IV are displayed in
Table 2. The N2–H2c…O3 hydrogen bonding assembles infinite
one-dimensional (1D) ribbons (C22(8)) made up of alternate
enantiomers running parallel to [100] direction in the chloroform
solvate described in this study (Fig. 3). The formation of N2–
H2c…O4 hydrogen-bonded dimers in Form I and Form III
contracts the C10–C11–S1–N2 dihedral angle in both polymorphs
with respect to Form IV, which has a higher value for this torsion
due to the ribbon assembly. As expected, all X–C11–S1–Y torsions
are directly influenced and their values considerably differ for the
two CTD conformers of Form IV and the antecedent crystal
phases.
Furthermore, the N2–H2c…O3 interactions (R22(8) assembly)
act as cross-linkers between layers of centrosymmetric dimers
stacked along the [100] direction. As in the crystal packing of CTD
Form I, the N1–H1 amine group of the isoindolinyl moiety is a
hydrogen bonding donor to the carbonyl O1 oxygen atom of the
same moiety from a neighboring molecule of CTD Form IV. This
Table 1 Selected dihedral angles (u) for R-enantiomers of CTD Form I,10 Form III,10 and Form IV (this study)
Structure part Torsion Form I Form III Form IV conformer A Form IV conformer B
Isoindolinyl ring C1–N1–C2–C3 20.1(2) 2.8(2) 20.2(6) 0.6(7)
C1–N1–C2–O1 2177.7(2) 2177.1(2) 179.4(5) 2179.6(5)
C2–N1–C1–C8 0.8(2) 24.6(2) 20.3(6) 20.6(6)
C3–C8–C1–N1 21.4(2) 4.6(2) 0.7(6) 0.4(6)
C8–C3–C2–O1 176.8(2) 2179.6(2) 2179.0(6) 179.9(6)
C8–C3–C2–N1 20.9(3) 0.5(3) 0.7(7) 20.3(7)
Sulfonamide C10–C11–S1–N2 109.6(2) 114.0(2) 128.3(4) 126.9(4)
C10–C11–S1–O3 24.9(2) 21.7(2) 11.9(5) 5.8(5)
C10–C11–S1–O4 2135.0(2) 2129.4(2) 2114.6(4) 2116.4(5)
C12–C11–S1–N2 267.0(2) 266.9(2) 254.1(5) 255.9(5)
C12–C11–S1–O3 178.5(2) 177.4(2) 2170.5(4) 2177.0(4)
C12–C11–S1–O4 48.4(2) 49.7(2) 63.0(5) 60.9(5)
C1–C9 bridge between the
benzene and isoindolinyl rings
C10–C9–C1–C8 172.2(2) 85.5(2) 103.2(6) 100.8(6)
C10–C9–C1–N1 274.2(2) 2160.3(2) 2145.7(5) 2147.8(5)
C10–C9–C1–O2 47.4(2) 237.7(3) 223.0(6) 224.1(7)
C14–C9–C1–C8 28.7(3) 293.7(2) 271.8(6) 275.6(6)
C14–C9–C1–N1 104.9(2) 20.5(3) 39.4(6) 35.8(7)
C14–C9–C1–O2 2133.5(2) 143.0(2) 162.1(5) 159.5(5)
Table 2 Geometry of hydrogen bonds in CTD Form IV. Distances and angles are given in angstroms (A˚) and degrees (u), respectively
(config.)-conformer donor–(config.)-conformer acceptor D–H…Aa D–H H…A D…A D–H…A
(R)-A–(S)-A N1A–H1A…O1Ab 0.86 2.05 2.891(6) 165
(R)-A–(S)-B O2A–H2A…O1Bc 0.82 1.91 2.730(4) 177
(R)-A–(S)-B N2A–H2cA…O3B 0.94 2.18 3.075(6) 159
(R)-A–(R)-B N2A–H2bA…Cl1Bd 0.84 2.78 3.511(6) 145
(S)-B–(R)-B N1B–H1B…O1Be 0.86 2.10 2.946(7) 166
(S)-B–(R)-A O2B–H2B…O1Af 0.82 1.95 2.744(4) 162
(S)-B–(R)-A N2B–H2cB…O3Ag 0.84 2.41 3.161(6) 149
(S)-B–(S)-A N2B–H2bB…Cl1Ad 0.83 2.87 3.663(6) 160
a D: hydrogen donor; A: hydrogen acceptor. Symmetry operators: b 1 2 x, 2 2 y, 2 z; c 1 + x, 1 + y, 2 1 + z; d 2 x, 1 2 y, 1 2 z; e 2 x,
2 y, 2 2 z; f x, 2 1 + y, 1 + z; g 2 1 + x, y, z.
This journal is  The Royal Society of Chemistry 2012 CrystEngComm, 2012, 14, 6173–6177 | 6175
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donation gives rise to centrosymmetric dimers whose conforma-
tion is identical (dimers ALA or BLB) (Fig. 4). These dimers are
further packed along the [100] direction through the O2–H2…O1
and N2–H2b…Cl1 hydrogen bonds (Fig. 4 and Table 2). The
O2–H2…O1 hydrogen bond involving the C2LO1 carbonyl and
O2–H2 hydroxyl moieties of the isoindolinyl moiety is responsible
for the connection between two enantiomeric conformers A and B
in CTD Form IV. This interaction also contributes to stack the
centrosymmetric dimers along the [100] direction in CTD Form I.
In the N2–H2b…Cl1 interactions, the amine group of the
sulfonamide moiety is a hydrogen bonding donor to chlorine
atoms of drug molecules stacked along the [100] direction. These
N2–H2b…Cl1 interactions occur between conformers A and B
(but with the same absolute stereochemistry) of CTD Form IV.
No N2–H2b…Cl1 contacts are observed in Form I and Form III.
Indeed, although the similarities between crystal packing of CTD
Form I and Form IV, the stacking fashion of one centrosymmetric
dimer on the top of one another differs for these solid state forms
of the drug. In Form I, the dimers are offset stacked but with the
planes crossing through the isoindolinyl moieties of both paired
molecules parallel placed on top of each other. In contrast, there is
no offset stacking in Form IV, which forces a bend of ca. 24u
between the planes passing through the isoindolinyl moieties of
two [100]-stacked dimers. Such a stacking fashion of the
centrosymmetric dimers changed with respect to Form I is also
related to the Form III-like conformation adopted by both
Fig. 3 The hydrogen bonds between sulfonamide moieties in Form I,10
Form III10 and Form IV.
Fig. 4 The centrosymmetric dimers and the stacking thereof in Form I10 and Form IV.
Fig. 5 (a) Empty and (b) chloroform-filled channels of CTD Form IV. A
transparent gray surface rendering is outlined in both panels. (c) Weak
non-classical hydrogen bonds between chloroform and drug conformers
(symmetry operator: (i) 1 2 x, 2 y, 1 2 z).
6176 | CrystEngComm, 2012, 14, 6173–6177 This journal is  The Royal Society of Chemistry 2012
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conformers of Form IV. Completing the crystal assembly of Form
IV, the accommodation of the stacked layers made up of
centrosymmetric dimers gives rise to holes distributed over the
[010] and [001] directions (Fig. 5). Chloroform solvents occupy
these holes, forming channels running parallel to the a axis. Within
the channels, CHCl3 participates in weak non-classical hydrogen
bonds with drug conformers as either a donor group (C1s–
H1a…O3a contact) or an acceptor group (C7b–H7b…Cl2s and
C7b–H7bI…Cl3s contacts; I = 1 2 x, 2 y, 1 2 z) (Fig. 5).
In summary, CTD form IV was prepared for the first time and
its single-crystal X-ray diffraction structure was determined. In
comparison with the antecedent polymorphs, namely, Form I and
Form III, its two conformers exhibit a dual structural feature, both
with a Form III-like conformation and a Form I-like crystal
packing, despite the different stacking fashion of its centrosym-
metric dimers. In this new solid state form, chloroform molecules
with a maximum stoichiometry of 0.25 mol per mol of the drug
play a stabilizing role in the assembly of Form IV by means of
occupying the channels formed in the crystals. At last, we believe
this study means a structural progress in terms of the chlortalidone
solid state polymorphism.
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